| name | Alfuzosin |
| Classification | Alpha-1 adrenergic antagonist |
| Pharmacokinetics | Alfuzosin is primarily metabolized in the liver, and its half-life is approximately 8-10 hours. It is well absorbed after oral administration, with peak plasma concentrations generally occurring within 2-4 hours. The drug is extensively bound to plasma proteins (approximately 96%). The metabolites are excreted primarily in the urine. Elimination half-life is about 8 hours. |
| suggested dosage | | male patient 25 70kg | Generally, the starting dose for benign prostatic hyperplasia (BPH) is 10 mg orally once daily. The dose may be increased to a maximum of 20 mg daily, divided into two doses, if necessary. Individual patient response and tolerance should be closely monitored. | | important note | Dosage must be individualized and should be carefully titrated based on the patient's response and tolerability. It's crucial to follow the prescribed dosage and consult a medical professional for any adjustments. |
|
| indications | Alfuzosin is primarily used to treat benign prostatic hyperplasia (BPH), which causes urinary symptoms such as difficulty starting urination, weak urine stream, and frequent urination, especially at night. |
| Safety in pregnancy | Alfuzosin is not recommended during pregnancy. Its use during pregnancy is not well-studied, and potential risks to the developing fetus are unknown. |
| Safety in breastfeeding | It is unknown whether alfuzosin is excreted in breast milk. Due to the potential for adverse effects in the infant, alfuzosin is generally not recommended during breastfeeding. |
| side effects | | 1 | Dizziness | | 2 | Headache | | 3 | Orthostatic hypotension (low blood pressure when standing up) | | 4 | Nausea | | 5 | Fatigue | | 6 | Abdominal pain | | 7 | Nasal congestion | | 8 | Vision changes (rare) | | 9 | Ejaculatory dysfunction (e.g., decreased libido, ejaculatory disorders) |
|
| alternatives | |
| contraindications | | 1 | Hypersensitivity to alfuzosin or other components of the medication. | | 2 | Severe hepatic impairment | | 3 | Severe hypotension | | 4 | Recent history of stroke or transient ischemic attack (TIA) |
|
| interactions | | 1 | Some medications may increase the risk of dizziness or low blood pressure if taken with alfuzosin, such as other antihypertensive drugs. Alcohol may also potentiate these effects. A detailed medication history is essential to assess any potential interactions. | | 2 | Antacids may reduce the absorption of alfuzosin, so it is recommended to take it at least 2 hours apart from antacids. |
|
| warnings and precautions | | 1 | Patients with a history of low blood pressure should be carefully monitored. | | 2 | Patients with liver disease should have their dose adjusted, if necessary. | | 3 | Sudden or abrupt cessation of alfuzosin may lead to rebound effects. The dose should be gradually reduced or tapered to minimize these effects. | | 4 | Caution is needed in elderly patients due to the increased risk of orthostatic hypotension. |
|
| additional informations | Alfuzosin is generally well-tolerated, but patients should be monitored for any signs of orthostatic hypotension, particularly when initiating treatment. Important lifestyle adjustments may include regular exercise, maintaining a healthy weight, and avoiding alcohol to potentially mitigate side effects. This is not exhaustive and a healthcare professional should be consulted before starting treatment. |
| patient specific considerations | For a 25-year-old male weighing 70 kg, the standard starting dosage and titration guidelines are appropriate. However, individual responses may vary and regular follow-up with a healthcare professional is essential. |
